Exploring the Cardiotoxicity Spectrum of Anti-Cancer Treatments: Definition, Classification, and Diagnostic Pathways
Early detection and treatment of cancer have led to a noticeable reduction in both mortality and morbidity. However, chemotherapy and radiotherapy could exert cardiovascular (CV) side effects, impacting survival and quality of life, independent of the oncologic prognosis. In this regard, a high clinical index of suspicion is required by the multidisciplinary care team in order to trigger specific laboratory tests (namely natriuretic peptides and high-sensitivity cardiac troponin) and appropriate imaging techniques (transthoracic echocardiography along with cardiac magnetic resonance, cardiac computed tomography, and nuclear testing (if clinically indicated)), leading to timely diagnosis. In the near future, we do expect a more tailored approach to patient care within the respective community along with the widespread implementation of digital health tools..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of Clinical Medicine - 12(2023), 4, p 1612 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ciro Mauro [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Cancer therapy-related cardiovascular toxicity |
|---|
| doi: |
10.3390/jcm12041612 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ080245811 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ080245811 | ||
| 003 | DE-627 | ||
| 005 | 20240413062818.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230310s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm12041612 |2 doi | |
| 035 | |a (DE-627)DOAJ080245811 | ||
| 035 | |a (DE-599)DOAJ8bc3788173e94651a206e9cc6711ee5e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Ciro Mauro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Exploring the Cardiotoxicity Spectrum of Anti-Cancer Treatments: Definition, Classification, and Diagnostic Pathways |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Early detection and treatment of cancer have led to a noticeable reduction in both mortality and morbidity. However, chemotherapy and radiotherapy could exert cardiovascular (CV) side effects, impacting survival and quality of life, independent of the oncologic prognosis. In this regard, a high clinical index of suspicion is required by the multidisciplinary care team in order to trigger specific laboratory tests (namely natriuretic peptides and high-sensitivity cardiac troponin) and appropriate imaging techniques (transthoracic echocardiography along with cardiac magnetic resonance, cardiac computed tomography, and nuclear testing (if clinically indicated)), leading to timely diagnosis. In the near future, we do expect a more tailored approach to patient care within the respective community along with the widespread implementation of digital health tools. | ||
| 650 | 4 | |a cardio-oncology | |
| 650 | 4 | |a cancer therapy-related cardiovascular toxicity | |
| 650 | 4 | |a chemotherapy | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Valentina Capone |e verfasserin |4 aut | |
| 700 | 0 | |a Rosangela Cocchia |e verfasserin |4 aut | |
| 700 | 0 | |a Filippo Cademartiri |e verfasserin |4 aut | |
| 700 | 0 | |a Ferdinando Riccardi |e verfasserin |4 aut | |
| 700 | 0 | |a Michele Arcopinto |e verfasserin |4 aut | |
| 700 | 0 | |a Maie Alshahid |e verfasserin |4 aut | |
| 700 | 0 | |a Kashif Anwar |e verfasserin |4 aut | |
| 700 | 0 | |a Mariano Carafa |e verfasserin |4 aut | |
| 700 | 0 | |a Andreina Carbone |e verfasserin |4 aut | |
| 700 | 0 | |a Rossana Castaldo |e verfasserin |4 aut | |
| 700 | 0 | |a Salvatore Chianese |e verfasserin |4 aut | |
| 700 | 0 | |a Giulia Crisci |e verfasserin |4 aut | |
| 700 | 0 | |a Roberta D’Assante |e verfasserin |4 aut | |
| 700 | 0 | |a Mariarosaria De Luca |e verfasserin |4 aut | |
| 700 | 0 | |a Monica Franzese |e verfasserin |4 aut | |
| 700 | 0 | |a Domenico Galzerano |e verfasserin |4 aut | |
| 700 | 0 | |a Vincenzo Maffei |e verfasserin |4 aut | |
| 700 | 0 | |a Alberto Maria Marra |e verfasserin |4 aut | |
| 700 | 0 | |a Alfredo Mazza |e verfasserin |4 aut | |
| 700 | 0 | |a Brigida Ranieri |e verfasserin |4 aut | |
| 700 | 0 | |a Anna D’Agostino |e verfasserin |4 aut | |
| 700 | 0 | |a Salvatore Rega |e verfasserin |4 aut | |
| 700 | 0 | |a Luigia Romano |e verfasserin |4 aut | |
| 700 | 0 | |a Sarah Scagliarini |e verfasserin |4 aut | |
| 700 | 0 | |a Chiara Sepe |e verfasserin |4 aut | |
| 700 | 0 | |a Olga Vriz |e verfasserin |4 aut | |
| 700 | 0 | |a Raffaele Izzo |e verfasserin |4 aut | |
| 700 | 0 | |a Antonio Cittadini |e verfasserin |4 aut | |
| 700 | 0 | |a Eduardo Bossone |e verfasserin |4 aut | |
| 700 | 0 | |a Andrea Salzano |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Clinical Medicine |d MDPI AG, 2013 |g 12(2023), 4, p 1612 |w (DE-627)DOAJ000006793 |x 20770383 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:4, p 1612 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/jcm12041612 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/8bc3788173e94651a206e9cc6711ee5e |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2077-0383/12/4/1612 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2077-0383 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 4, p 1612 | ||